ESTRO 2024 - Abstract Book

S1949

Clinical - Mixed sites, palliation

ESTRO 2024

Conclusion:

Histology and systemic therapy had a significant impact on LC after pRT, but significant differences in LC based on TVD strategy were not observed. Our data suggest that a reduction of target volumes in pRT is safe as it does not lead to lower LC rates compared to extended volume pRT. Non-inferiority analyses for reduced volume pRT in larger patient cohorts addressing treatment toxicity as well are warranted, and prospective data with structured imaging follow-up protocols are needed to provide a solid data basis for contouring recommendations in pRT after stabilization surgery for spinal metastases.

Keywords: spinal metastases, postoperative radiotherapy

1840

Digital Poster

Validation of the METABANK score in oligometastatic patients after SBRT in a tertiary care center.

Marta Camacho Manzanares 1 , Julen Azcona 1 , Maria Elena Centelles 1 , Francisco Luis Mesa 1 , Carolina de la Pinta 1 , Mercedes Martin 1 , Margarita Martin 1 , Raul Hernanz 1 , Eva Fernandez 1 , Asuncion Hervas 1 , Fernando Campos 1 , Jose Dominguez 1 , Carmen Vallejo 1 , Teresa Muñoz 1 , Marina Alarza 1 , David Sevillano 2 , Miguel Camara 3 , Juan David Garcia 3 , Sonia Rubia 3 , Sonsoles Sancho 1 1 Ramon y Cajal Universitary Hospital, Radiation Oncology, Madrid, Spain. 2 Ramon y Cajal Universitary Hospital, Radiopysics, Madrid, Spain. 3 Ramon y Cajal Universitary Hospital, Radiophysics, Madrid, Spain

Purpose/Objective:

Stereotactic body radiation therapy (SBRT) is an effective treatment for multi-site oligometastatic disease and an alternative to surgery with a low side-effect profile, but given the high variability of this disease it is very difficult to estimate its prognosis. The METABANK Score is a tool that aims to predict the prognosis of oligometastatic patients treated with SBRT. This tool evaluates 4 factors and each of them has a score: male sex (4 points), synchronous disease (2 points), brain metastases (7 points), no adenocarcinoma (7 points) and KPS<80 (8 points); and based on the score acquired, 4 risk groups were defined: low risk (0-2), low intermediate (3-8 points), high intermediate (9-13 points) and high (>14 points).

Material/Methods:

Between February 2004 and April 2023, oligometastatic patients treated with SBRT at the Hospital Universitario Ramón y Cajal were included up to a maximum of 5 metastases. These patients were classified into the 4 METABANK groups according to the METABANK tool score and the median survival (in months) and overall survival at 2 and 5 years were calculated.